| 货号 | 包装规格 | 操作 |
|---|---|---|
| SML0083-50MG | 50 mg |
GSK 1059615 is a phosphatidylinositol-3-kinases (PI3K) inhibitor. GSK 1059615 inhibits proliferation of breast cancer BT474 cells via four different mechanisms that include retinoblastoma 1 (RB1)-mediated cell cycle arrest, elevated forkhead box protein O1 (FOXO) signaling, deduced MYC and transferrin receptor (TFRC) signaling and decreased cellular metabolism. Additionally, GSK 1059615 can suppress cell proliferation by decreasing mitogen-activated protein kinase (MAPK) signaling and imparts sensitivity to phosphoinositide 3-kinase (PI3K) inhibitor in cells resistant to the protein kinase B or AKT inhibitor. GSK 1059615 functions as a druggable target to reduce radiation-induced apoptosis in NCCIT cells.PMID 22747550 GSK 1059615 has entered clinical trial in patients with solid tumors or lymphoma and refractory malignancies.PMID 19644473PMID 24900173
GSK 1059615是PI 3激酶抑制剂
GSK 1059615是PI 3激酶的强效抑制剂（IC 50 = 2 nM）
该化合物是用于激酶磷酸酶生物学研究的特色产品。单击此处了解更多特色激酶磷酸酶生物学产品。访问sigma.com/discover-bsm了解更多用于其他研究领域的生物活性小分子。
该化合物由葛兰素史克公司开发。要浏览其他制药公司开发的化合物和批准的药物/候选药物列表，请单击此处。
| 英文名称 | GSK 1059615 sodium salt hydrate |
| CAS 号 | 1356195-42-0 |
| 经验分子式 | N-甲基-N |
| 分子量 | 355.35（以无水物计） |
| UNSPSC | 12352203 |
| NACRES | NA.44 |
| 质量等级 | 100 |
| SMILES字符串 | O.[Na+].O=C1[N-]C(=O)C(\S1)=C\c2ccc3nccc(-c4ccncc4)c3c2 |
| InChI | 1S/C18H11N3O2S.Na.H2O/c22-17-16（24-18（23）21-17）10-11-1-2-15-14（9-11）13（5-8-20-15）12-3-6-19-7-4-12;;/h1-10H，（H，21，22，23）;;1H2/q;+1;/p-1/b16-10-;; |
| InChI key | CPS-FLPKAINGSA-M型断路器 |
| 形态 | 粉末 |
| 颜色 | 黄色 |
| 溶解性 | 水：≥8 mg/mL |
| 发起者 | 葛兰素史克 |
| 储存温度 | 2-8°C |
| 包装规格（货号 SML0083-50MG） | 50 mg |
